Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease

Figures & data

Figure 1 Systematic search of PubMed returned 26 studies. Following review of the titles, abstracts, and full-text, 7 studies were included in the present review.

Table 1 Number of patients in each contributing article of the review

Author/article	Patients (N)
Yu et al^Citation8	21
van Rhee et al^Citation9	19
Casper et al^Citation11	79
Mayer et al^Citation12	17
Koenig et al^Citation5	1
Mohammed et al^Citation4	1
van Rhee et al^Citation14	23

Table 2 Study characteristics and patient demographics

Country	Studies (cases)
USA	5 (75)
Multinational study	2 (96)
Study design
Clinical trials	5 (169)
Case report	2 (2)
Demographics	N (range)
Total patients	161
Mean age	56.8 (18–78 years)
Ethnicity, (n)
Caucasian	65
Asian	41
African American	2
Gender, (n)
Female	65
Male	89

Table 3 Clinical presentation of multicentric Castleman’s disease (N=171)

	N (%)
Symptoms
B-symptoms	15/25 (60)
Hepatosplenomegaly	7/25 (28)
Fever	5/25 (20)
Pleural effusion/ascites	4/25 (16)
Organ failure	2/25 (8)
Bone pain	1/25 (4)
Confusion	1/25 (4)
Plasmablastic microlymphoma	1/25 (4)
Lymph node architecture
Hyaline-vascular variant	62/152 (40.8)
Plasmacytic variant	54/152 (35.5)
Mixed variant	36/152 (23.7)
Past medical history
Asthma	4/14 (28.6)
Thrombotic thrombocytopenic purpura	2/14 (14.3)
Unspecified autoimmune disorder	2/14 (14.3)
Idiopathic thrombocytopenic purpura	1/14 (7.1)
Systemic lupus erythematosus	1/14 (7.1)
Antiphospholipid syndrome	1/14 (7.1)
Diffuse large B-cell lymphoma	1/14 (7.1)
Hodgkin’s lymphoma	1/14 (7.1)
Sarcoidosis	1/14 (7.1)
Mean duration (months)	4.8 (range 1.3–93.2)

YuLTuMCortesJClinical and pathological characteristics of HIV- and HHV-8 negative Castleman diseaseBlood Adv20171291216581668

 Web of Science ®Google Scholar

van RheeFCasperCVoorheesPA phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman diseaseOncotarget201563030408301926327301

 PubMed Web of Science ®Google Scholar

CasperCChaturvediSMunshiNAnalysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman diseaseClin Cancer Res201521194294430426124203

 PubMed Web of Science ®Google Scholar

MayerCLXieLBandekarRDose selection of siltuximab for multicentric Castleman’s diseaseCancer Chemother Pharmacol20157551037104525784388

 PubMed Web of Science ®Google Scholar

KoenigGStevensTMPekerDPlasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapyHistopathology201567693093225900626

 PubMed Web of Science ®Google Scholar

MohammedAJankuFQiMKurzrockRCastleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case reportJ Med Case Rep2015914525884809

 PubMedGoogle Scholar

van RheeFFayadLVoorheesPSiltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s diseaseJ Clin Oncol201028233701370820625121

 PubMed Web of Science ®Google Scholar